NASDAQ:NKTX Nkarta (NKTX) Stock Price, News & Analysis $3.23 +0.04 (+1.25%) (As of 11/4/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Nkarta Stock (NASDAQ:NKTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Nkarta alerts:Sign Up Key Stats Today's Range$3.14▼$3.4550-Day Range$3.08▼$6.5152-Week Range$1.90▼$16.24Volume713,834 shsAverage Volume1.14 million shsMarket Capitalization$227.91 millionP/E RatioN/ADividend YieldN/APrice Target$17.50Consensus RatingBuy Company OverviewNkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.Read More… The most serious warning of my career (Ad)With the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the financial world in two the moment the polls close. I predict they could see investment losses of 50% (or more) in the weeks following the presidential election. Click here now to grab your seat now. Nkarta Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks55th Percentile Overall ScoreNKTX MarketRank™: Nkarta scored higher than 55% of companies evaluated by MarketBeat, and ranked 513th out of 972 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.6 / 5Analyst RatingBuy Consensus RatingNkarta has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNkarta has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Nkarta's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Nkarta are expected to decrease in the coming year, from ($1.92) to ($1.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nkarta is -1.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nkarta is -1.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNkarta has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Nkarta's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.77% of the outstanding shares of Nkarta have been sold short.Short Interest Ratio / Days to CoverNkarta has a short interest ratio ("days to cover") of 18.2, which indicates bearish sentiment.Change versus previous monthShort interest in Nkarta has recently increased by 10.38%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNkarta does not currently pay a dividend.Dividend GrowthNkarta does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted14.77% of the outstanding shares of Nkarta have been sold short.Short Interest Ratio / Days to CoverNkarta has a short interest ratio ("days to cover") of 18.2, which indicates bearish sentiment.Change versus previous monthShort interest in Nkarta has recently increased by 10.38%, indicating that investor sentiment is decreasing significantly. News and Social Media1.8 / 5News Sentiment0.20 News SentimentNkarta has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Nkarta this week, compared to 2 articles on an average week.Search Interest6 people have searched for NKTX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Nkarta to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Nkarta insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.70% of the stock of Nkarta is held by insiders.Percentage Held by Institutions80.54% of the stock of Nkarta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nkarta's insider trading history. Receive NKTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nkarta and its competitors with MarketBeat's FREE daily newsletter. Email Address NKTX Stock News HeadlinesNkarta (NKTX) Stock: Looking For UpsideOctober 31, 2024 | seekingalpha.comNkarta to Participate in Upcoming Investor ConferenceSeptember 3, 2024 | globenewswire.comUrgent: This election is riggedIf you missed it, my emergency election broadcast is now available - but will be removed soonNovember 4, 2024 | Porter & Company (Ad)Buy Rating Affirmed for Nkarta Amid Strategic Focus and Promising Clinical TrialsAugust 17, 2024 | markets.businessinsider.comBuy Rating on Nkarta Amid Promising Clinical Trials and Solid Financial PositionAugust 15, 2024 | markets.businessinsider.comNkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL PatientsAugust 15, 2024 | seekingalpha.comWhy Nkarta Stock Is Soaring TodayAugust 14, 2024 | fool.comNkarta upgraded at Raymond James on valuationAugust 14, 2024 | msn.comSee More Headlines NKTX Stock Analysis - Frequently Asked Questions How have NKTX shares performed this year? Nkarta's stock was trading at $6.60 at the beginning of the year. Since then, NKTX stock has decreased by 51.1% and is now trading at $3.23. View the best growth stocks for 2024 here. How were Nkarta's earnings last quarter? Nkarta, Inc. (NASDAQ:NKTX) issued its earnings results on Tuesday, August, 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.49) by $0.15. When did Nkarta IPO? Nkarta (NKTX) raised $150 million in an initial public offering on Friday, July 10th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Cowen, Evercore ISI, Stifel and Mizuho Securities served as the underwriters for the IPO. Who are Nkarta's major shareholders? Top institutional investors of Nkarta include SG Americas Securities LLC (0.04%), Bleakley Financial Group LLC (0.03%), Holistic Planning LLC (0.01%) and GAMMA Investing LLC (0.02%). Insiders that own company stock include Ra Capital Management, LP, Simeon George, Paul J Hastings, James Trager, David Shook, Alicia J Hager and Ralph Brandenberger. View institutional ownership trends. How do I buy shares of Nkarta? Shares of NKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Nkarta own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nkarta investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), CrowdStrike (CRWD) and Arista Networks (ANET). Company Calendar Last Earnings8/13/2024Today11/04/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NKTX CUSIPN/A CIK1787400 Webwww.nkartatx.com Phone925-407-1049FaxN/AEmployees140Year FoundedN/APrice Target and Rating Average Stock Price Target$17.50 High Stock Price Target$25.00 Low Stock Price Target$13.00 Potential Upside/Downside+422.4%Consensus RatingBuy Rating Score (0-4)3.29 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-117,500,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-28.83% Return on Assets-22.53% Debt Debt-to-Equity RatioN/A Current Ratio15.90 Quick Ratio15.91 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.56 per share Price / Book0.60Miscellaneous Outstanding Shares70,560,000Free Float64,420,000Market Cap$236.38 million OptionableOptionable Beta0.87 Unlock the Potential in Options TradingOptions trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.Get This Free Report This page (NASDAQ:NKTX) was last updated on 11/4/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredA Totally New ‘Income Coin’Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, i...Crypto 101 Media | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nkarta, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nkarta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.